Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80534 |
Name | myxofibrosarcoma |
Definition | A sarcoma that arises from the soft tissue and is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer sarcoma myxofibrosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
NCT03474094 | Phase II | Atezolizumab | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) | Recruiting | GBR | FRA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Active, not recruiting | USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04216953 | Phase Ib/II | Atezolizumab + Cobimetinib | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) | Active, not recruiting | FRA | 0 |
NCT04242238 | Phase I | Avelumab + Vimseltinib | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | Active, not recruiting | USA | 0 |
NCT04332874 | Phase II | Pembrolizumab | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | Recruiting | USA | 0 |
NCT04420975 | Phase I | BO-112 + Nivolumab | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04480502 | Phase II | Envafolimab + Ipilimumab Envafolimab | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC) | Active, not recruiting | USA | GBR | 0 |
NCT04906876 | Phase II | Docetaxel + Elraglusib + Gemcitabine | 9-ING-41Combined With Chemotherapy in Adolescents and Adults | Withdrawn | USA | 0 |
NCT04996004 | Phase Ib/II | Doxorubicin + TTI-621 | A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma | Terminated | USA | 0 |
NCT05116800 | Phase II | Docetaxel + Elraglusib + Gemcitabine | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Withdrawn | USA | 0 |
NCT05597917 | Phase III | Trabectedin Trabectedin + tTF-NGR | tTF-NGR Randomized Study - STS (TRABTRAP) | Recruiting | DEU | AUT | 0 |
NCT05711615 | Phase I | Pegylated liposomal doxorubicin + Peposertib | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Recruiting | USA | 0 |
NCT05809830 | Phase Ib/II | Doxorubicin Doxorubicin + LB-100 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) | Recruiting | ESP | 0 |
NCT05821231 | Phase I | MEDI5752 | Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (MEDISARC-SBRT) | Recruiting | FRA | 0 |
NCT06021626 | Phase I | CRD3874 | A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer | Recruiting | USA | 0 |
NCT06273852 | Phase I | PBA-0405 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT06422806 | Phase III | Doxorubicin Doxorubicin + Pembrolizumab | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Recruiting | USA | 0 |
NCT06660810 | Phase I | Talimogene laherparepvec | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | Not yet recruiting | USA | 0 |